Step 4Combine states for remission, drug-responsive and drug-dependent into a single state

4.1 Identify chances of being in each state from Silverstein et al.26
RemissionMildDrug-responsiveDrug-dependentDrug-refractorySurgeryPost-surgeryDeath
Time spent in states (total person-years)737.38471.3517.5372.5037.3726.95570.08
Selected states (total person-years)737.3817.5372.50
Probability of being in state89.12%2.12%8.76%
Identify total chances of remaining in any remission-type state
RemissionMildDrug-responsiveDrug-dependentDrug-refractorySurgeryPost-surgeryDeath
Remission0.969410.011430.012750.00641
Mild
Drug-responsive0.870670.032970.061090.03527
Drug-dependent0.969780.010020.013330.00688
Drug-refractory0.142770.749780.069560.03789
Surgery0.104240.031510.341750.52250
Post-surgery0.010760.002180.005220.98184
Death
4.2, 4.3, 4.4 Apply chances of being in each state from Silverstein et al.26to weight outcomes
RemissionMildDrug-responsiveDrug-dependentDrug-refractorySurgeryPost-surgeryDeath
Remission0.967350.011760.013830.00706
Mild
Drug-responsive
Drug-dependent
Drug-refractory0.142770.749780.069560.03789
Surgery0.104240.031510.341750.52250
Post-surgery0.010760.002180.005220.98184
Death

From: 4, Assessment of cost-effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.